Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors

PURPOSE: Omacetaxine mepesuccinate is a first-in-class cephalotaxine demonstrating clinical activity in chronic myeloid leukemia. A subcutaneous (SC) formulation demonstrated efficacy and safety in phase 1/2 trials in patients previously treated with ≥1 tyrosine kinase inhibitor. This study assessed...

Descripción completa

Detalles Bibliográficos
Autores principales: Nemunaitis, John, Mita, Alain, Stephenson, Joe, Mita, Monica M., Sarantopoulos, John, Padmanabhan-Iyer, Swami, Nanda, Nisha, Gleich, Lyon, Benichou, Annie-Claude, Craig, Adam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3535355/
https://www.ncbi.nlm.nih.gov/pubmed/23053254
http://dx.doi.org/10.1007/s00280-012-1963-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3535355/
https://www.ncbi.nlm.nih.gov/pubmed/23053254
http://dx.doi.org/10.1007/s00280-012-1963-2

Ejemplares similares